Corporate Profile

Secura Bio^® is a pharmaceutical company committed to giving patients access to innovative therapies.

Headquartered in Las Vegas, Nevada.

Leadership

Chip R. Romp

PRESIDENT & CHIEF EXECUTIVE OFFICER

With over 25 years in the pharmaceutical industry Mr. Romp has proven his ability to build the pharmaceutical commercialization process from development stage to successful global product. He has an extensive background in various therapeutic areas with an emphasis on oncology and hematology. He spent 12 years at Genentech in a wide range of sales, marketing, and development roles spanning their entire oncology/immunology product portfolio. Mr. Romp was previously Executive Vice President, US Commercial at Seagen, Inc. where he was a member of the Executive Committee. He oversaw the entire Seagen Commercial organization in addition to broader roles in corporate communications, investor relations, and business development.

WILL BROWN, MBA

CHIEF FINANCIAL OFFICER

Mr. Brown is an executive with deep experience in capital markets, accounting, and finance. He formerly was the Chief Financial Officer and Interim Chief Executive Officer of ObsEva SA (NASDAQ: OBSV / SIX: OBSN) where he led the company through a restructuring, successfully generating a >$100 million strategic disposition. He also was the Chief Financial Officer of Altimmune, Inc. (NASDAQ: ALT) where he was critical in the company’s transformation and growth through more than $300 million of new equity issuances and a strategic acquisition. Mr. Brown was a consultant to private and public companies in a variety of accounting and financial matters as managing partner of Redmont Advisors and CPAs.

Mr. Brown was a CPA (2006 to 2022, AL# 10198), and earned both his MBA and B.S. from Auburn University Montgomery.

Juan Estruch

Head of Corporate Development

Dr. Estruch has over 25 years of experience in Life Sciences and was a co-founder of Secura. He has extensive experience in product assessment, corporate strategy, corporate development and served in increasingly senior management roles. Prior to Secura, Dr. Estruch served in senior positions or as head of corporate development for Ciba-Geigy, Novartis, Diversa, Prometheus and Genoptix. He has a proven track record for identifying under-exploited biopharmaceutical assets that are candidates for repositioning or relaunch.

Dr. Estruch earned a Ph.D. in Biochemistry and Molecular Biology from the University of Essen, Germany and Valencia, Spain. He also earned an MBA from the Fuqua School of Business, Duke University.

Christiane Langer, MD

SENIOR VICE PRESIDENT, HEAD OF CLINICAL & MEDICAL AFFAIRS

Dr. Langer holds more than 20 years of clinical research and medical affairs experience, most recently having served as Senior Vice President, Global Medical Affairs at BeiGene and before that Senior Vice President, Global Medical Affairs for Atara Biotherapeutics and Vice President of Global Medical Affairs for Agios Pharmaceuticals. She also held senior medical positions for Roche/Genentech in both the U.S. and Germany. In these roles, she built and managed medical affairs teams, led successful launches, nurtured strong relationships in the scientific community with professional societies, cooperative and patient advocacy groups and established deep expertise around cell therapies and various hematology- and oncology-related indications. Prior to these positions, Dr. Langer held positions of increasing responsibility within clinical development at Bristol Myers Squibb in the U.S. and Europe.

Dr. Langer earned her medical degree from the University of Freiburg, Germany, and spent her residency in obstetrics and gynecology with a focus on gynecologic oncology at the University Hospital Hannover, Germany. She completed postdoctoral studies on apoptosis in breast cancer under Dr. John Reed at the Burnham Institute in La Jolla, Calif.

Gregory S. Wessels

SENIOR VICE PRESIDENT, COMMERCIAL STRATEGY AND OPERATIONS

Mr. Wessels has over 25 years of life sciences experience in sales, marketing and commercialization strategy, most recently having served as Senior Vice President and Chief Commercial Officer of Aprea Therapeutics. Mr. Wessels also held global and regional hematology/oncology positions of increasing responsibility over more than 10 years at Celgene Corporation, culminating as Executive Director, Lymphoma Global Marketing. Prior to joining Celgene he spent 11 years with Sanofi US in sales, marketing and business planning roles.

Mr. Wessels received a BS in Biochemistry from the University of Notre Dame and an MBA from the Kellogg School of Management at Northwestern University.

Board Members

Patrick Vink, MD, MBA

Chairman

Dr. Vink brings over 35 years of industry experience and currently serves as Chairman and Board member of several public and private biopharma companies, both in the U.S. and in Europe, including F2G Ltd and Essential Pharma. Throughout his Board tenures, he has played an active role in initial public offerings, achieving meaningful development, regulatory and commercial milestones, and facilitating geographic expansions. As a Board member of Amryt Pharma, he was involved in the recent sale to Chiesi Farmaceutici for over $1.4 billion, and as Chair of the Board of Biognosys, he guided their transaction with Bruker in 2023. Dr. Vink previously served as Executive Vice President and Chief Operating Officer at Cubist, Inc., a leader in the acute care hospital market. In this role, Dr. Vink oversaw all worldwide commercial and technical operations until the successful acquisition of Cubist by Merck for $9.5 billion in 2015. Prior to Cubist, Dr. Vink held several key leadership roles across the biopharmaceutical industry, including head of the Global Hospital Business at Mylan Inc., the Global Hospital Business at Sandoz (a division of Novartis) and the head of the International Business at Biogen. Dr. Vink holds an M.D. from the University of Leiden and an MBA from the University of Rochester.

Chip R. Romp

President and CEO, Board Member

With over 25 years in the pharmaceutical industry Mr. Romp has proven his ability to build the pharmaceutical commercialization process from development stage to successful global product. He has an extensive background in various therapeutic areas with an emphasis on oncology and hematology. He spent 12 years at Genentech in a wide range of sales, marketing, and development roles spanning their entire oncology/immunology product portfolio. Mr. Romp was previously Executive Vice President, US Commercial at Seagen, Inc. where he was a member of the Executive Committee. He oversaw the entire Seagen Commercial organization in addition to broader roles in corporate communications, investor relations, and business development.

Jeffrey A. Ferrell

Board Member

Jeffrey A. Ferrell is the founder of Athyrium (2008) and currently serves as the firm’s Managing Partner. Mr. Ferrell has substantial investment experience in the life sciences sector across a wide range of asset classes and transaction structures.

Prior to forming Athyrium, Mr. Ferrell served in several capacities at Lehman Brothers, including overseeing life sciences investments for Global Trading Strategies (a principal investment group within Lehman) and as Vice President in Lehman Brothers’ Private Equity division focused on life sciences investments. Prior to joining Lehman in 2001, he was Principal at Schroder Ventures Life Sciences (SVLS) based in Boston. Investments Mr. Ferrell has been involved with include: Sequenom, Bioenvision (acquired by Genzyme), Jazz Pharmaceuticals, Orthovita (acquired by Stryker), Nektar Therapeutics, ISTA Pharmaceuticals, Lpath, Auxilium Pharmaceuticals, KaloBios, Fluidigm, and more. Mr. Ferrell graduated with an AB in Biochemical Sciences from Harvard College.

Mr. Ferrell currently serves on the board of Progenity (NASDAQ: PROG).

Joerg Moeller, MD

Board Member

Joerg Moeller, MD is the CEO of Antag Therapeutics, a biotechnology company dedicated to developing innovative peptide-based therapies to address obesity and related cardiometabolic disorders. With over 30 years of experience in the pharmaceutical industry, Dr. Moeller has a proven track record of developing and launching innovative and competitive drugs in various therapeutic areas, such as cardiovascular, oncology, hematology, ophthalmology, women’s health, dermatology and infectious diseases. As the former Head of Global Research and Development at Bayer Pharmaceuticals and a member of Bayer Pharma’s Executive Committee, he has successfully led large global organizations in research, development, and regulatory compliance, and has built growth portfolios through productive and collaborative partnerships with academic institutions, biotech companies, and pharmaceutical peers. Dr. Moeller most recently was the Chief Executive Officer and Executive Board Member of BenevolentAI, a leader in AI augmented drug discovery. Previously, he was the Global Head of Research and Development at LEO Pharma A/S, a leading dermatology company. He is passionate about fostering a culture of excellence, innovation, teamwork, and diversity in his teams and across the industry. He is also an advocate of digitalization and artificial intelligence as drivers of R&D efficiency and quality.